You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Critical errors* with Ellipta compared to other commonly used asthma inhalers

Ellipta is an easy-to-use inhaler 1 that helps your patients with asthma receive the benefit of their medication 2

*Defined as errors that are likely to result in no or minimal medication being inhaled.

If an inhaled medication is not delivered correctly it may not work as effectively as it could 3

  • Commonly used inhaler devices are associated with a significant number of handling errors 3
  • Inhaler handling errors can impact the effectiveness of drug delivery, and may lead to sub-optimal disease control 3
  • A recent study of commonly used inhalers has shown that patients can make one or more critical errors that are likely to result in no or minimal medication being inhaled 2

What is the Ellipta Critical Errors in Asthma Study? 2

This was a randomised, open-label, placebo, crossover, multicentre study involving 162 adult patients (ITT) with asthma who were naïve to the Ellipta inhaler and one of the other inhaler devices.

Each sub-study compared Ellipta with one of three other inhaler devices: Diskus, MDI and Turbohaler. At one single visit, patients received inactive placebo inhalers in a crossover study design, after reading the patient information leaflet. 2

The primary endpoint was the percentage of patients making one or more critical errors with an inhaler following reading of the patient information leaflet. 2

  • All participants were receiving treatment for asthma and were naïve to using the Ellipta inhaler and at least one of the other inhaler devices
  • Participants received inactive treatment (placebo) via the Ellipta inhaler and one of the three other inhaler devices depending on the study to which they were allocated
  • Patients were randomised to determine the sequence in which they demonstrated inhaler use
  • At the study visit, participants were asked to demonstrate use of the inhaler after reading the patient information leaflet; any errors made were recorded by a study nurse using a specific checklist for each inhaler
  • The primary endpoint was the percentage of participants making at least one critical error after reading the patient information leaflet
  • A critical error is defined as an error that is likely to result in no, or minimal medication being inhaled

Demographic characteristics of asthma population

 

What were the results of the Ellipta Critical Errors in Asthma Study?

Critical errors* with Ellipta compared to other commonly used asthma inhalers 2

*Defined as errors that are likely to result in no or minimal medication being inhaled.

Below, you will find a list of critical errors for each inhaler: 2

Ellipta

  • Failed to open cover
  • Shook the device upside down after dose preparation
  • Exhaled directly into mouthpiece
  • No seal by the lips round the mouthpiece during the inhalation

Diskus

  • Failed to open cover
  • Lever is not pushed back
  • Shook the device after dose preparation
  • Exhaled directly into mouthpiece
  • No seal by the lips round the mouthpiece during inhalation

MDI

  • Failed to remove cap
  • Did not shake the device
  • Failed to place device in mouth
  • No dose actuated during an inhalation manoeuvre
  • Dose coordination was so poor that patient is likely to have received no dose or only received minimal dose
     
     
Turbohaler
  • Failed to remove cap
  • Did not hold device upright (±45⁰) during dose preparation
  • Base not twisted fully backwards and forwards, no click heard
  • Shook the device after dose preparation
  • Exhaled directly into mouthpiece
  • No seal by the lips round the mouthpiece during the inhalation

Find out more information and watch our videos on how to use the Ellipta

How to use Ellipta

Prescribing Information

Relvar Ellipta (fluticasone furoate/vilanterol)
Prescribing Information

Seretide Diskus (salmeterol xinofoate/fluticasone propionate)
Prescribing Information

Seretide Evohaler (salmeterol xinofoate/fluticasone propionate) 
Prescribing Information

References

  1. Svedsater H et al. BMC Pulm Med 2013; 13:72.
  2. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26: doi:10.1038/npjpcrm.2016.79.
  3. Melani AS et al. Respir Med 2011; 105:930–938.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the GSK group of companies. ©2017 GSK group of companies or its licensor.